172.82
5.56 (3.32%)
5.56 (3.32%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| United Therapeutics Corporation | UTHR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 5.56 | 3.32% | 172.82 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 165.70 | 165.70 | 173.72 | 172.82 | 167.26 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 138.00 | 333.00 | 195.00 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 8,216 | 719,231 | $ 170.03 | $ 122,290,171 | 374,783 | 75.58 - 173.72 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:57:36 | priorref | 168 | $ 172.82 | USD |
United Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 7.68B | 44.44M | 39.03M | $ 1.45B | $ 548.66M | -2.45 | 15.30 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | -1.51k | 0.20% |
United Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical UTHR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 167.75 | 173.72 | 160.5015 | 165.71 | 387,908 | 5.07 | 3.02% |
| 1 Month | 149.07 | 173.72 | 143.35 | 156.97 | 389,936 | 23.75 | 15.93% |
| 3 Months | 123.10 | 173.72 | 120.76 | 142.13 | 404,033 | 49.72 | 40.39% |
| 6 Months | 121.33 | 173.72 | 98.37 | 125.69 | 357,064 | 51.49 | 42.44% |
| 1 Year | 91.27 | 173.72 | 75.58 | 113.27 | 462,734 | 81.55 | 89.35% |
| 3 Years | 140.98 | 173.72 | 74.31 | 106.43 | 437,809 | 31.84 | 22.58% |
| 5 Years | 133.44 | 173.72 | 74.31 | 115.55 | 480,166 | 39.38 | 29.51% |
United Therapeutics Description
| United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for pulmonary arterial hypertension largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Nearly all of its sales are generated within the United States. United also markets a pediatric oncology drug, but its focus largely remains in pulmonary hypertension. |
